CRISPR Therapeutics (NASDAQ:CRSP) Trading 8% Higher Following Analyst Upgrade

CRISPR Therapeutics AG (NASDAQ:CRSP)’s stock price was up 8% on Friday after TD Cowen raised their price target on the stock from $40.00 to $45.00. TD Cowen currently has a hold rating on the stock. CRISPR Therapeutics traded as high as $52.78 and last traded at $52.85. Approximately 415,556 shares changed hands during trading, a decline of 76% from the average daily volume of 1,723,382 shares. The stock had previously closed at $48.93.

Several other equities analysts have also recently issued reports on the stock. Needham & Company LLC upped their target price on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Friday. Wedbush decreased their price objective on shares of CRISPR Therapeutics from $13.00 to $9.00 and set an “outperform” rating for the company in a report on Wednesday, November 5th. Bank of America dropped their target price on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Chardan Capital cut their target price on shares of CRISPR Therapeutics from $82.00 to $74.00 and set a “buy” rating for the company in a research report on Wednesday, November 26th. Finally, Citizens Jmp lowered their price target on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a report on Friday, January 30th. Eleven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $67.24.

Insiders Place Their Bets

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 60,000 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total value of $3,613,800.00. Following the transaction, the chief executive officer directly owned 134,201 shares in the company, valued at approximately $8,082,926.23. This trade represents a 30.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.30% of the company’s stock.

More CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Casgevy commercial momentum—management highlighted that Casgevy generated about $54M in Q4 and $116M for full‑year 2025, supporting the view that adoption for the company’s approved SCD/TDT therapy is expanding and producing meaningful sales. CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
• Positive Sentiment: Analyst upgrade/price‑target lift—Needham raised its price target to $82 and maintained a Buy rating, signaling institutional conviction that shares have upside on continued commercial execution. CRSP Price Target Raised by Needham
• Neutral Sentiment: Official business update and results—CRISPR published its Q4 and full‑year 2025 results and a business update emphasizing pipeline progress and upcoming label expansion plans; this is informative for longer‑term thesis but contains limited near‑term financial guidance. CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Positive retail narrative—an upbeat Fool feature framed the company as a “blastoff‑ready” biotech pick for 2026, which can boost retail buying interest but is opinion‑driven. The Blastoff-Ready Biotech Stock You’ll Kick Yourself for Not Buying in 2026
• Neutral Sentiment: Short‑interest data appears anomalous—recent reports show short interest listed as 0 shares (likely a reporting/data issue), so short‑interest signaling is unclear and should be treated cautiously.
• Negative Sentiment: Quarterly miss and wider loss—CRSP reported Q4 EPS of ($1.37) versus consensus ($1.15) and revenue of $0.86M versus $4.72M expected; revenue fell sharply year‑over‑year, underscoring near‑term financial pressure and a negative margin/earnings backdrop. CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Ramirez Asset Management Inc. purchased a new stake in CRISPR Therapeutics in the fourth quarter worth about $26,000. Rothschild Investment LLC grew its stake in shares of CRISPR Therapeutics by 836.7% during the 4th quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after acquiring an additional 502 shares during the period. Thurston Springer Miller Herd & Titak Inc. grew its stake in shares of CRISPR Therapeutics by 196.9% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after acquiring an additional 382 shares during the period. Atlantic Union Bankshares Corp purchased a new stake in CRISPR Therapeutics in the 2nd quarter worth approximately $33,000. Finally, Thompson Investment Management Inc. bought a new stake in CRISPR Therapeutics during the 3rd quarter worth approximately $33,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Trading Up 8.5%

The company has a market cap of $5.06 billion, a P/E ratio of -8.14 and a beta of 1.72. The business’s 50 day simple moving average is $54.22 and its 200 day simple moving average is $57.37.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). The firm had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.72 million. CRISPR Therapeutics had a negative return on equity of 26.69% and a negative net margin of 16,569.77%.The business’s revenue for the quarter was down 97.8% on a year-over-year basis. During the same period last year, the company earned ($1.01) earnings per share. Sell-side analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.